Etizolam in the treatment of generalized anxiety disorder: a controlled clinical trial.
A total of 45 patients with generalized anxiety disorder were treated twice daily for 2 weeks, on a double-blind basis, with 0.5 mg etizolam, 0.5 mg alprazolam or 3 mg bromazepam, and symptoms were assessed using Hamilton's rating scale for anxiety and Hamilton's rating scale for depression. Patients then received the same drug for a further 2 weeks, the drugs being given three times daily if a poor response was observed during the first 2 weeks. All drugs displayed equivalent anxiolytic activity after 2 weeks, but etizolam displayed a progressive increase in anxiolytic activity over 4 weeks of treatment. Etizolam also possessed a more marked antidepressant effect than did alprazolam or bromazepam. There were no differences in the tolerability of the three drugs.
Bertolino
A
A
Casa Divina Provvidenza, Bisceglie, Bari, Italy.
Mastucci
E
E
Porro
V
V
Corfiati
L
L
Palermo
M
M
Ecari
U
U
Ceccarelli
G
G
D000328:Adult; D000525:Alprazolam / Q000627:therapeutic use*; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D001960:Bromazepam / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003975:Diazepam / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D014149:Tranquilizing Agents / Q000627:therapeutic use*
D014151:Anti-Anxiety Agents; D014149:Tranquilizing Agents; C044610:etizolam; D003975:Diazepam; D001960:Bromazepam; D000525:Alprazolam